Last reviewed · How we verify

Stempeucel® — Competitive Intelligence Brief

Stempeucel® (Stempeucel®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allogeneic mesenchymal stem cell therapy. Area: Regenerative Medicine / Orthopedics.

marketed Allogeneic mesenchymal stem cell therapy Regenerative Medicine / Orthopedics Biologic Live · refreshed every 30 min

Target snapshot

Stempeucel® (Stempeucel®) — Cell Biopeutics Resources Sdn Bhd. Stempeucel® is an allogeneic mesenchymal stem cell therapy that promotes tissue regeneration and reduces inflammation through paracrine signaling and immunomodulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Stempeucel® TARGET Stempeucel® Cell Biopeutics Resources Sdn Bhd marketed Allogeneic mesenchymal stem cell therapy
ASCs (Cx401, company code) ASCs (Cx401, company code) Tigenix S.A.U. phase 3 Allogeneic mesenchymal stem cell therapy
Rexlemestrocel-L + HA Mixture Rexlemestrocel-L + HA Mixture Mesoblast, Ltd. phase 3 Allogeneic mesenchymal stem cell therapy
ALLO-ASC-DFU ALLO-ASC-DFU Anterogen Co., Ltd. phase 3 Allogeneic mesenchymal stem cell therapy
Cellgram-LC Cellgram-LC Pharmicell Co., Ltd. phase 3 Allogeneic mesenchymal stem cell therapy
FURESTEM-AD Inj. FURESTEM-AD Inj. Kang Stem Biotech Co., Ltd. phase 3 Allogeneic mesenchymal stem cell therapy
CARTISTEM® + Debridement CARTISTEM® + Debridement Medipost, Inc. phase 3 Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allogeneic mesenchymal stem cell therapy class)

  1. Tigenix S.A.U. · 2 drugs in this class
  2. Cell Biopeutics Resources Sdn Bhd · 1 drug in this class
  3. Kang Stem Biotech Co., Ltd. · 1 drug in this class
  4. Anterogen Co., Ltd. · 1 drug in this class
  5. Mesoblast, Ltd. · 1 drug in this class
  6. Pharmicell Co., Ltd. · 1 drug in this class
  7. Medipost, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Stempeucel® — Competitive Intelligence Brief. https://druglandscape.com/ci/stempeucel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: